...
NTLASMALL

Intellia Therapeutics, Inc.

HealthcareBiotechnology
$13.78
$0.00(-3.50%)
52W$5.90
$28.25
FinancialsValuationvs ALNY
Updated Mar 1, 12:00 AM
RSI63
RS Rating79/99
Beta1.52
Volatility101%
F-Score3/9
Mkt Cap$1.6B
CONSOLIDATING

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

CONSOLIDATING

Intellia Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 79), indicating performance broadly in line with the market. Earnings growth of 36% provides fundamental context to the price action. Investors should exercise caution due to high volatility (101% annualized), which requires wider risk management.

Relative Strength
79
out of 99
Average
Trend Score
2/4
Minervini Criteria
CONSOLIDATING
Risk (Beta)
1.52
vs S&P 500
HIGH BETA
52W Position
35%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

CONSOLIDATING2/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$11.86
50 SMA > 100 SMA$13.02
100 SMA > 150 SMA$13.03
150 SMA > 200 SMA$12.24

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$12.65+8.89%ABOVE
50 SMA$11.86+16.24%ABOVE
100 SMA$13.02+5.88%ABOVE
150 SMA$13.03+5.73%ABOVE
200 SMA$12.24+12.58%ABOVE

Price Performance

1D-3.5%
1W+4.7%
1M-0.3%
3M+53.3%
6M+18.8%
YTD+49.6%
1Y+36.6%
3Y-30.0%
52-Week Trading Range35% from low
$13.78
52W Low$5.90
52W High$28.25

Technical Indicators

RSI (14)BULLISH
62.7
305070
VCP ScoreCOOL
5/10
Base depth: 65.0%

Risk Profile

Beta
1.52
52W Vol
101%
ATR
$0.78
Max DD (1Y)
-71%

Volume Analysis

Today
13
50D Avg
4.41M
Vol Ratio
0.00x
Liquidity
MODERATE

Earnings Momentum

Q1'25+2%
$-1.10
Q2'25+36%
$-0.98
Q3'25+31%
$-0.92
Q4'25+36%
$-0.81
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-100.00%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+27.43%

Stock Price CAGR

10 Years:-4.61%
5 Years:-26.45%
3 Years:-30.00%
1 Year:+36.57%

Return on Equity

10Y Avg:-37.4%
5Y Avg:-45.1%
3Y Avg:-49.9%
Last Year:-61.5%

Key Metrics

Market Cap$1.6B
Gross Margin—
Net Margin—
Piotroski F-Score3/9

More NTLA Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

NTLA vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 79 meansNTLA outperformed 79% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.52 means 52% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 3/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is NTLA in an uptrend right now?

NTLA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.

Is NTLA overbought or oversold?

NTLA's RSI (14) is 63. The stock is in neutral territory, neither overbought nor oversold.

Is NTLA outperforming the market?

NTLA has a Relative Strength (RS) Rating of 79 out of 99. NTLA is performing about average compared to the market.

Where is NTLA in its 52-week range?

NTLA is trading at $13.78, which is 49% of its 52-week high ($28.25) and 35% above its 52-week low ($5.90).

How volatile is NTLA?

NTLA has a Beta of 1.52 and 52-week volatility of 101%. It's more volatile than the S&P 500 - expect bigger swings.